Table 2. Comparison of overall survival and disease free survival time in patients with RORα and RORγ expression in primary melanomas and metastases (Log-rank Mantel-Cox Test).
| Expression of: | Total cases (n) | Deaths (n/%) | Median/mean overall survival (days) | Statistically significant p values | Metastases (n/%) | Median/mean disease free survival (days) | Statistically significant p values |
|---|---|---|---|---|---|---|---|
| nuclear RORα | |||||||
| None | 22 | 14/63.6 | 618.3/530.0 | 13/59.1 | 288.3/69.00 | ||
| Low | 14 | 9/64.3 | 843.1/876.0 | P>0.05* | 11/78.6 | 275.4/127.0 | P>0.05* |
| High | 43 | 16/37.2 | 896.1/899.0 | P=0.0064* | 15/34.9 | 689.7/597.0 | P=0.0302* |
| P>0.05^ | P=0.0030^ | ||||||
| cytoplasmic RORα | |||||||
| None | 14 | 8/57.1 | 720.7/876.0 | 7/50.0 | 470.3/263.0 | ||
| Low | 18 | 11/61.1 | 813.4/819.0 | P>0.05* | 12/66.7 | 338.7/152.0 | P>0.05* |
| High | 47 | 20/42.6 | 841.4/825.0 | P>0.05* | 21/44.7 | 580.9/429.0 | P>0.05* |
| P>0.05^ | P>0.05^ | ||||||
| nuclear RORγ | |||||||
| None | 32 | 20/62.5 | 733.9/779.0 | 19/59.4 | 298.3/114.0 | ||
| Low | 33 | 18/55.5 | 872.4/829.0 | P>0.05* | 18/55.5 | 539.2/284.0 | P>0.05* |
| High | 14 | 1/7.1 | 860.7/877.0 | P=0.0053* | 2/14.3 | 842.7/877.0 | P=0.0091* |
| P=0.0373^ | P=0.0337^ | ||||||
| cytoplasmic RORγ | |||||||
| None | 53 | 30/56.6 | 713.9/714.0 | 32/60.4 | 340.5/127.0 | ||
| Low | 23 | 8/34.8 | 1007.0/940.0 | P=0.0080* | 7/30.4 | 818.7/916.0 | P=0.0006* |
| High | 3 | 0/0.0 | 1101.0/1204.0 | P=0.0231* | 1/33.3 | 1101.0/1204.0 | P=0.0405* |
| P>0.05^ | P>0.05^ |
*
versus No ROR
^
versus Low ROR